Kourie Hampig Raphael, Kanaan Hassan, Awada Gil, Awada Ahmad Hussein
Oncology Department, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon.
Medical Oncology Clinic, Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium.
Future Oncol. 2017 May;13(12):1097-1103. doi: 10.2217/fon-2016-0494. Epub 2017 Feb 28.
Brain metastases (BMs) are representing a new challenge for the oncologist; their incidence is increasing due to the better overall survival and systemic disease control in many malignancies, consequent to new potent cytotoxic and targeted therapies. In the era of immunotherapies, checkpoint inhibitors are representing a new therapeutic option in different solid tumors and settings; preliminary results showed potential activity of these agents in patients with BM, when administered as single agent or in combination with radiation therapy. After presenting the arguments in favor of this new strategy, we reported the preliminary results of the trials evaluating these agents in BM, we described the ongoing trials and we discussed the potential role of these agents in the BM treatment.
脑转移瘤（BMs）对肿瘤学家来说是一个新的挑战；由于许多恶性肿瘤的总体生存率提高和全身疾病得到更好控制，其发病率正在上升，这得益于新型强效细胞毒性和靶向治疗。在免疫治疗时代，检查点抑制剂在不同实体瘤及治疗环境中代表着一种新的治疗选择；初步结果显示，这些药物作为单一药物或与放射治疗联合使用时，对脑转移瘤患者具有潜在活性。在阐述了支持这一新策略的论据后，我们报告了评估这些药物在脑转移瘤中疗效的试验的初步结果，描述了正在进行的试验，并讨论了这些药物在脑转移瘤治疗中的潜在作用。
